Division of Hematology and Bone Marrow Transplant, Max Super-speciality Hospital, India.
Division of Hematology and Bone Marrow Transplant, Max Super-speciality Hospital, India.
Blood Cells Mol Dis. 2021 May;88:102464. doi: 10.1016/j.bcmd.2020.102464. Epub 2020 Jul 2.
Pure red cell aplasia is a known complication after ABO incompatible stem cell transplant. Due to rarity of disease, no established treatment guidelines are available for PRCA. Daratumumab is a monoclonal antibody against CD38 expressed by plasma cells. In this report we present our experience of successfully managing a patient of post-transplant PRCA with daratumumab. Our patient had failed multiple lines of therapy prior to receiving daratumumab. Response was seen after the 3rd weekly dose of daratumumab.
纯红细胞再生障碍性贫血是 ABO 不相容干细胞移植后的已知并发症。由于疾病罕见，尚无针对 PRCA 的既定治疗指南。达雷妥尤单抗是一种针对浆细胞表达的 CD38 的单克隆抗体。在本报告中，我们介绍了成功使用达雷妥尤单抗治疗移植后 PRCA 患者的经验。我们的患者在接受达雷妥尤单抗治疗之前已经失败了多种治疗方案。在接受达雷妥尤单抗第 3 周剂量后观察到了反应。
